Oligoprogression and Metastasis‐Directed Therapy During Systemic Therapy for Metastatic Renal Cell Carcinoma
International Journal of Urology · 2026-11 · 33 (11)
DOI: 10.1111/iju.70716 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Urology, online erschienen am 13.11.2026. Verfasst von Takuto Shimizu und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Nara Medical University, Kashihara, Nara, Japan. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit nennt 12 Literaturangaben.
Abstract (Originalsprache)
Objectives
To characterize the frequency and clinical patterns of oligoprogression during systemic therapy for metastatic renal cell carcinoma (mRCC) and evaluate outcomes following metastasis‐directed therapy (MDT).
Methods
We retrospectively reviewed 261 patients with mRCC treated between 2007 and 2025. Oligoprogression was defined as progression in five or fewer lesions despite otherwise controlled disease. Cumulative incidence was estimated using competing‐risk analysis. Associations between MDT and treatment‐line outcomes were evaluated using time‐dependent Cox regression.
Results
Among 544 evaluable treatment‐line assessments from 261 patients, oligoprogression occurred in 63 (11.6%), representing 63 unique patients. Crude frequencies were 6.1%, 16.7%, and 16.5% during first‐, second‐, and third‐line therapy, respectively. The cumulative incidence was 8.8% at 6 months and 10.8% at 12 months. Fifty‐four patients (85.7%) had one or two progressing lesions. MDT was performed in 21 patients, whereas 42 received no MDT. Patients selected for MDT had a lower oligoprogressive lesion burden. In multivariable time‐dependent analysis, MDT was not associated with treatment‐line escalation alone (hazard ratio [HR], 1.05; 95% confidence interval [CI], 0.41–2.71), but was associated with a lower hazard of treatment‐line escalation or death (HR, 0.42; 95% CI, 0.19–0.94). The cumulative incidence of local progression after MDT was 26.7% at 12 months and 39.9% at 24 months.
Conclusions
Oligoprogression occurred in a clinically relevant subset of patients with mRCC. Although MDT was associated with favorable composite outcomes, substantial treatment selection limits causal interpretation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, Nara Medical University, Kashihara, Nara, Japan.
- Department of Urology, Matsusaka Cho General Hospital, Matsusaka, Mie, Japan.
- Department of Urology, Yamato Takada Municipal Hospital, Yamato Takada, Nara, Japan.
- Department of Urology, Tane General Hospital, Osaka, Osaka, Japan.
- Department of Urology, Saiseikai Chuwa Hospital, Sakurai, Nara, Japan.
- Department of Urology, Nara City Hospital, Nara, Nara, Japan.
ORCID-Profile: Takuto Shimizu, Yuki Oda, Kota Iida, Takashi Iwamoto, Akira Tachibana, Mitsuru Tomizawa, Kenta Onishi, Shunta Hori, Yosuke Morizawa, Daisuke Dotoh, Yasushi Nakai, Nobumichi Tanaka, Makito Miyake
Zitieren
APA
Shimizu, T., Oda, Y., Nishimura, N., Iemura, Y., Iida, K., Tatsumi, Y., Sakamoto, K., Iwamoto, T., Ichikawa, K., Kuwada, M., Takamatsu, N., Tachibana, A., Tomizawa, M., Onishi, K., Hori, S., Morizawa, Y., Dotoh, D., Nakai, Y., Tanaka, N., & Miyake, M. (2026). Oligoprogression and Metastasis‐Directed Therapy During Systemic Therapy for Metastatic Renal Cell Carcinoma. International Journal of Urology, 33(11). https://doi.org/10.1111/iju.70716
Vancouver
Shimizu T, Oda Y, Nishimura N, Iemura Y, Iida K, Tatsumi Y, et al. Oligoprogression and Metastasis‐Directed Therapy During Systemic Therapy for Metastatic Renal Cell Carcinoma. International Journal of Urology. 2026;33(11). doi:10.1111/iju.70716
BibTeX
@article{Shimizu2026,
author = {Shimizu, Takuto and Oda, Yuki and Nishimura, Nobutaka and Iemura, Yusuke and Iida, Kota and Tatsumi, Yoshihiro and Sakamoto, Keiichi and Iwamoto, Takashi and Ichikawa, Kazuki and Kuwada, Masaomi and Takamatsu, Norimi and Tachibana, Akira and Tomizawa, Mitsuru and Onishi, Kenta and Hori, Shunta and Morizawa, Yosuke and Dotoh, Daisuke and Nakai, Yasushi and Tanaka, Nobumichi and Miyake, Makito},
title = {Oligoprogression and Metastasis‐Directed Therapy During Systemic Therapy for Metastatic Renal Cell Carcinoma},
journal = {International Journal of Urology},
year = {2026},
volume = {33},
number = {11},
doi = {10.1111/iju.70716}
}
EUVIMED